Kate Newbold

Kate Newbold, MBBS, MRCP, MD is Consultant Clinical Oncologist and Lead Clinician for Thyroid Cancer at The Royal Marsden NHS Foundation Trust, one of the world's leading cancer centers. She is among the UK's foremost experts in the multidisciplinary management of thyroid cancers, specializing in the integration of radioiodine therapy, external beam radiotherapy, and systemic targeted agents for differentiated, medullary, and anaplastic thyroid cancers. Her clinical and research work has shaped British and European guidelines for thyroid cancer management. Dr. Newbold has led multiple national and international clinical trials evaluating novel radioiodine sensitization strategies, intensity-modulated radiation therapy (IMRT) techniques for locally advanced thyroid cancer, and combinations of targeted agents with locoregional treatments. She has contributed to studies of selumetinib and trametinib as redifferentiation agents to restore radioiodine avidity in RAI-refractory differentiated thyroid cancer. Her leadership of the UK Thyroid Cancer Outcomes registry has provided population-level data informing national treatment pathways. Beyond her clinical program, Dr. Newbold is an active educator and advocate for thyroid cancer patients, serving on the British Thyroid Association executive council, contributing to European Thyroid Association guidelines, and chairing national multidisciplinary team guidance working groups. She has authored over 100 peer-reviewed publications and is a frequent invited speaker at international oncology and endocrinology conferences.